公开(公告)号：US12252478B2

公开(公告)日：2025-03-18

申请号：US17858701

申请日：2022-07-06

Applicant: NOVARTIS AG

Inventor： Stephanie Kay Dodd ,  Arnaud Grandeury ,  Emmanuel Suffert ,  Evgenia Rousaki

IPC: C07D401/14 ,  A61K9/20

Abstract: The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US20210169854A1

公开(公告)日：2021-06-10

申请号：US17025853

申请日：2020-09-18

Applicant: NOVARTIS AG

Inventor： Mangesh Sadashiv Bordawekar ,  Stephanie Kay Dodd ,  Cornelius Stephan Harlacher ,  Jithin K John ,  Pravin Karmuse ,  Saran Kumar ,  Sangeetha Kumari ,  Vishnu Maremanda ,  Parthkumar Patel ,  Kanhaiyalal Patidar ,  Kapil Patil ,  Alan Edward Royce ,  Shaikh Mohsin Shaikh Hamid ,  Mauro Serratoni ,  Henricus Lambertus Gerardus Maria Tiemessen ,  Daya D Verma ,  Sunita Yadav

IPC: A61K31/4152 ,  A61K47/22 ,  A61K9/48 ,  G01N33/15

Abstract: Disclosed are novel pharmaceutical formulation containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof and processes for preparing the same.

公开(公告)号：US11407735B2

公开(公告)日：2022-08-09

申请号：US16874622

申请日：2020-05-14

Applicant: NOVARTIS AG

Inventor： Stephanie Kay Dodd ,  Arnaud Grandeury ,  Emmanuel Suffert ,  Evgenia Rousaki

IPC: C07D401/14 ,  A61K9/20

Abstract: The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5 -yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US20150125475A1

公开(公告)日：2015-05-07

申请号：US14381513

申请日：2013-03-07

Applicant: Novartis AG

Inventor： Stephanie Kay Dodd ,  Siddhartha Jain

IPC: A61K31/675 ,  A61K39/39 ,  C07F9/6561

CPC classification number: A61K31/675 ,  A61K39/39 ,  A61K2039/55511 ,  C07F9/6561 ,  Y02A50/466

Abstract: The invention is in the field of salt forms of an immunopotentiator compound and their formulation for in vivo use. In particular the invention relates to arginine salts.

Abstract translation: 本发明在免疫增强剂化合物的盐形式及其用于体内使用的制剂领域。 特别地，本发明涉及精氨酸盐。

公开(公告)号：US12252479B2

公开(公告)日：2025-03-18

申请号：US17858713

申请日：2022-07-06

Applicant: NOVARTIS AG

Inventor： Stephanie Kay Dodd ,  Arnaud Grandeury ,  Emmanuel Suffert ,  Evgenia Rousaki

IPC: C07D401/14 ,  A61K9/20

Abstract: The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US10174006B2

公开(公告)日：2019-01-08

申请号：US14292082

申请日：2014-05-30

Applicant: Novartis AG

Inventor： Malay Ghosh ,  Christopher Michael Adams ,  Stephanie Kay Dodd ,  Stephen Hedrick Poor

IPC: A61K31/55 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/724 ,  C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K9/08 ,  A61K47/38

Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).

公开(公告)号：US09320748B2

公开(公告)日：2016-04-26

申请号：US14381513

申请日：2013-03-07

Applicant: Novartis AG

Inventor： Stephanie Kay Dodd ,  Siddhartha Jain

IPC: C07F9/6561 ,  A61K39/39 ,  A61K31/675 ,  A61K39/00

CPC classification number: A61K31/675 ,  A61K39/39 ,  A61K2039/55511 ,  C07F9/6561 ,  Y02A50/466

Abstract: The invention is in the field of salt forms of an immunopotentiator compound and their formulation for in vivo use. In particular the invention relates to arginine salts.

Abstract translation: 本发明在免疫增强剂化合物的盐形式及其用于体内使用的制剂领域。 特别地，本发明涉及精氨酸盐。

公开(公告)号：US20140364392A1

公开(公告)日：2014-12-11

申请号：US14292082

申请日：2014-05-30

Applicant: Novartis AG

Inventor： Malay Ghosh ,  Christopher Michael Adams ,  Stephanie Kay Dodd ,  Stephen Hedrick Poor

IPC: C07D403/12 ,  A61K31/55 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4439 ,  C07D519/00 ,  C07D413/14 ,  C07D403/14 ,  C07D487/04 ,  C07D471/04 ,  C07D495/04 ,  A61K31/724 ,  C07D401/12

CPC classification number: C07D403/12 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/724 ,  A61K47/02 ,  A61K47/10 ,  A61K47/186 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00

Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino) methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).

Abstract translation: 本发明涉及提供含有1H-吲哚-1-甲酰胺的多剂量局部眼用组合物及其用于治疗眼科疾病的用途。 更具体地说，本发明涉及含有1H-吲哚-1-甲酰胺（例如，N-（1-甲基-5-甲氧基苯基） - （三氟甲基）-1H-吡唑-3-基）-5 - （（6 - （（甲基氨基）甲基）嘧啶-4-基）氧基）-1H-吲哚-1-甲酰胺）及其用于治疗 眼后部的眼部疾病如年龄相关性黄斑变性（AMD）。